Status:
COMPLETED
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Cancer
Eligibility:
All Genders
Up to 120 years
Brief Summary
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer. PURPOSE: This laboratory study is l...
Detailed Description
OBJECTIVES: * Optimize and standardize the in vitro cell kill assay using human white blood cells and human cancer cell lines from patients with metastatic cancer and from healthy participants. * Det...
Eligibility Criteria
Inclusion
- Meets 1 of the following criteria:
- Diagnosis of metastatic cancer including, but not limited to, any of the following:
- Stage IV non-small cell lung cancer
- Extensive-stage small cell lung cancer
- Metastatic testicular cancer
- Stage IV breast carcinoma
- Stage III or IV ovarian carcinoma
- Stage IV endometrial carcinoma
- Stage IV prostate carcinoma
- Stage IV colorectal or pancreatic cancer
- Stage IV renal cancer
- Stage III or IV non-Hodgkin's lymphoma
- Stage IV bladder cancer
- Stage III multiple myeloma (Salmon-Durie staging)
- Metastatic melanoma
- Metastatic sarcoma
- Healthy participant, meeting the following criteria:
- No prior cancer
- Over 50 years of age
Exclusion
- Serious medical or psychiatric condition that would preclude study compliance
- Chemotherapy or radiotherapy within the past 3 months (patient)
- Prior immunosuppressive therapy or radiotherapy for any disease (healthy participant)
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 23 2009
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00899496
Start Date
September 1 2005
End Date
October 23 2009
Last Update
May 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157-1096